Search Results - "Galazka, Marlena"

Structural Factors Affecting Cytotoxic Activity of (E)-1-(Benzo[d ][1,3]oxathiol-6-yl)-3-phenylprop-2-en-1-one Derivatives by Konieczny, Marek T., Bułakowska, Anita, Polak, Justyna, Pirska, Danuta, Konieczny, Wojciech, Gryń, Patrycja, Skladanowski, Andrzej, Sabisz, Michał, Lemke, Krzysztof, Pieczykolan, Anna, Gałązka, Marlena, Wiciejowska, Katarzyna, Wietrzyk, Joanna

“…Derivatives of (E)‐1‐(5‐alkoxybenzo[d][1,3]oxathiol‐6‐yl)‐3‐phenylprop‐2‐en‐1‐one demonstrated exceptionally high in vitro cytotoxic activity, with IC50 values…”
Get full text

AD-O53.2—a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L by Pieczykolan, Jerzy S., Kubiński, Konrad, Masłyk, Maciej, Pawlak, Sebastian D., Pieczykolan, Anna, Rózga, Piotr K., Szymanik, Michał, Gałązka, Marlena, Teska-Kamińska, Małgorzata, Żerek, Bartłomiej, Bukato, Katarzyna, Poleszak, Katarzyna, Jaworski, Albert, Strożek, Wojciech, Świder, Robert, Zieliński, Rafał

“…Summary Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptors became promising molecules for selective targeting of tumor cells…”
Get full text

Novel engineered TRAIL‐based chimeric protein strongly inhibits tumor growth and bypasses TRAIL resistance by Rozga, Piotr, Kloska, Damian, Pawlak, Sebastian, Teska‐Kaminska, Malgorzata, Galazka, Marlena, Bukato, Katarzyna, Pieczykolan, Anna, Jaworski, Albert, Molga‐Kaczmarska, Anna, Kopacz, Aleksandra, Badyra, Bogna, Kachamakova‐Trojanowska, Neli, Zolnierkiewicz, Olga, Targosz‐Korecka, Marta, Poleszak, Katarzyna, Szymanik, Michal, Zerek, Bartlomiej, Pieczykolan, Jerzy, Jozkowicz, Alicja, Grochot‐Przeczek, Anna

“…Targeting of the TRAIL‐DR4/5 pathway was proposed as a promising approach for specific induction of apoptosis in cancer cells. Clinical trials, however, showed…”
Get full text

Abstract 4471: AD-O64.4 - a novel bioconjugate for tumor-targeted drug delivery by Strozek, Wojciech, Pieczykolan, Anna, Zerek, Bartlomiej, Szymanik, Michal, Jaworski, Albert, Galazka, Marlena, Bukato, Katarzyna, Rozga, Piotr, Pawlak, Sebastian, Poleszak, Katarzyna, Teska-Kaminska, Malgorzata, Pieczykolan, Jerzy

“…Although standard chemotherapy is still one of the most effective treatment for many types of cancer - often causes side effects. Chemotherapeutic agents…”
Get full text

Abstract 2773: AD-O56.9: A fusion of TRAIL/Apo2L with a membrane disrupting peptide as a novel anticancer therapeutic by Zerek, Bartlomiej Maciej, Szymanik, Michal, Rozga, Piotr Kamil, Pieczykolan, Anna, Galazka, Marlena, Bukato, Katarzyna, Jaworski, Albert, Poleszak, Katarzyna, Pawlak, Sebastian Dominik, Teska-Kaminska, Malgorzata, Strozek, Wojciech, Pieczykolan, Jerzy Szczepan

“…Background The tumor necrosis factor related apoptosis-inducing ligand (TRAIL/Apo2L) is a member of the TNF superfamily that initiates apoptosis of tumor cells…”
Get full text

Abstract 5073: Novel fusion molecule with high dual antiangiogenic and anticancer potential by Pieczykolan, Jerzy S., Rozga, Piotr, Pieczykolan, Anna, Zerek, Bartlomiej, Pawlak, Sebastian D., Szymanik, Michal, Jaworski, Albert, Galazka, Marlena, Wiciejowska, Katarzyna, Strozek, Wojciech, Teska - Kaminska, Malgorzata, Kutner, Lukasz, Grochot - Przeczek, Anna, Kahmakowa - Trojanowska, Neli

“…One of the most important mechanisms of tumorgenesis is formation of new blood vessels and tissue remodeling. Vascular endothelial growth factor (VEGF) is one…”
Get full text

Abstract 5488: Fusion protein capable to initiate two apoptotic pathways in cancer cells resistant to classical PARA's by Pieczykolan, Jerzy S., Pawlak, Sebastian D., Zerek, Bartlomiej M., Rozga, Piotr K., Pieczykolan, Anna, Szymanik, Michal, Jaworski, Albert, Galazka, Marlena, Strozek, Wojciech, Wiciejowska, Katarzyna, Teska-Kaminska, Malgorzata, Kutner, Lukasz

“…Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) is a promising antitumor agent, but its clinical utility in human malignancies is limited…”
Get full text

AD-053.2—a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L by PIECZYKOLAN, Jerzy S, KUBINSKI, Konrad, BUKATO, Katarzyna, POLESZAK, Katarzyna, JAWORSKI, Albert, STROZEK, Wojciech, SWIDER, Robert, ZIELINSKI, Rafał, MASLYK, Maciej, PAWLAK, Sebastian D, PIECZYKOLAN, Anna, ROZGA, Piotr K, SZYMANIK, Michał, GALAZKA, Marlena, TESKA-KAMINSKA, Małgorzata, ZEREK, Bartłomiej

Get full text

Abstract 2276: Induction of apoptosis and inhibition of angiogenesis by novel fusion protein - AD-O54.9 as a new preclinical strategy in cancer treatment by Rózga, Piotr, Pieczykolan, Jerzy, Zerek, Bartłomiej, Pieczykolan, Anna, Gałązka, Marlena, Bukato, Katarzyna, Szymanik, Michał, Jaworski, Albert, Pawlak, Sebastian, Teska-Kamińska, Małgorzata, Grochot-Przęczek, Anna

“…Background For almost two decades tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) has been under extensive development as a potential…”
Get full text